Scots reimburse Iluvien, but no for BindRen
This article was originally published in Scrip
Executive Summary
The Scottish Medicines Consortium has agreed to reimburse Alimera's chronic diabetic macular edema drug Iluvien (fluocinolone acetonide) following a full resubmission from the company. But it was a no for Mitsubishi Pharma's hyperphosphatemia drug BindRen (colestilan).